Georgia's Online Cancer Information Center


back

Head and Neck Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Head and Neck Cancer
Cancer Type = Head and Neck Cancer
NCI ID Cancer Type Trial Name
There are currently 36 active Head and Neck Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Cancer Type
Head and Neck Cancer
NCT ID
NCT04534205
Protocol IDs
BNT113-01
NCI-2021-03177
2020-001400-41
2.
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03978689
Protocol IDs
Cue-101-01
NCI-2019-04589
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
3.
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Cancer Type
Breast Cancer, Cervical Cancer, Gynecologic Cancers, Head and Neck Cancer, Ovarian Cancer
NCT ID
NCT04682431
Protocol IDs
PY159-2-01
NCI-2021-01998
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Head and Neck Cancer
NCT ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
5.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (1)
Emory University School of Medicine
Atlanta
6.
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Cancer Type
Head and Neck Cancer, Neuroendocrine Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT04211337
Protocol IDs
17478
J2G-MC-JZJB
2019-001978-28
NCI-2020-00277
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Cancer Type
Head and Neck Cancer
NCT ID
NCT03752398
Protocol IDs
XmAb23104-01
NCI-2019-00828
DUET-3
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
8.
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03769506
Protocol IDs
ASP-1929-301
NCI-2019-01324
9.
Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT05387915
Protocol IDs
WINSHIP5566-22
NCI-2022-02855
STUDY00004187
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
10.
Chemotherapy before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients with Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03493425
Protocol IDs
EA3163
NCI-2017-01364
EA3163
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT05334069
Protocol IDs
A212102
A212102
A212102
NCI-2022-02477
Treatment Sites (1)
Low Country Cancer Care Associates, PC
Savannah
12.
Comparing an Alternative Surgical Procedure, Sentinel Lymph Node (SLN) Biopsy, with Standard Neck Dissection for Patients with Early-Stage Oral Cavity Cancer
Cancer Type
Head and Neck Cancer
NCT ID
NCT04333537
Protocol IDs
NRG-HN006
NRG-HN006
NCI-2020-01542
13.
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined with Radiation for Patients with Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05050162
Protocol IDs
NRG-HN009
NRG-HN009
NCI-2021-08925
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
14.
De-intensified Radiation Therapy with Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients with Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03952585
Protocol IDs
NRG-HN005
NRG-HN005
NCI-2019-03015
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Grady Memorial Hospital
Atlanta
15.
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Cancer Type
Breast Cancer, Cervical Cancer, Esophogeal Cancer, Head and Neck Cancer, Hodgkin Lymphoma, Lung Cancer, Lymphoma, Stomach/ Gastric Cancer
NCT ID
NCT03674567
Protocol IDs
FLX475-02
NCI-2019-00102
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
FS118 First in Human Study in Patients With Advanced Malignancies
Cancer Type
Head and Neck Cancer, Hematopoietic Malignancies
NCT ID
NCT03440437
Protocol IDs
FS118-17101
NCI-2018-01062
17.
Head and Neck cancERs International cOviD-19 collabOraTion
Cancer Type
COVID-19, Head and Neck Cancer, Thyroid Cancer
NCT ID
NCT04632173
Protocol IDs
HERODOTUS
NCI-2021-11878
18.
Implementation and Effectiveness of HN-STAR in Managing the Health of Head and Neck Squamous Cell Cancer Survivors
Cancer Type
Head and Neck Cancer
NCT ID
NCT04208490
Protocol IDs
WF-1805CD
WF-1805CD
WF-1805CD
NCI-2019-03600
19.
Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT02135042
Protocol IDs
NRG-HN001
U10CA021661
U10CA180868
NCI-2014-00635
RTOG-1305
Treatment Sites (4)
Emory Proton Therapy Center
Atlanta
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
20.
Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients with Stage III-IVB Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT01893307
Protocol IDs
2012-0825
NCI-2013-01879
21.
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT04428151
Protocol IDs
7902-009
NCI-2020-04563
2019-000569-19
E7080-G000-228
LEAP-009
MK-7902-009
22.
Pembrolizumab and Cabozantinib in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer That Cannot Be Removed by Surgery
Cancer Type
Head and Neck Cancer
NCT ID
NCT03468218
Protocol IDs
Winship4234-17
NCI-2017-02419
IRB00100269
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
23.
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cancer Type
Head and Neck Cancer
NCT ID
NCT04815720
Protocol IDs
VX15/2503-12
NCI-2021-10364
KEYNOTE B84
24.
Pepinemab with or without Ipilimumab and/or Nivolumab in Treating Patients with Stage I-IVA Head and Neck Squamous Cell Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03690986
Protocol IDs
Winship4402-18
NCI-2018-01263
IRB00103534
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
25.
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Cancer Type
Head and Neck Cancer, Sarcoma, Solid Tumor
NCT ID
NCT04541108
Protocol IDs
PBI-MST-01
NCI-2021-10892
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
26.
Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer
Cancer Type
Head and Neck Cancer
NCT ID
NCT01311063
Protocol IDs
RTOG0920-VA
RAC# 2101-074
Treatment Sites (1)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
27.
Radiation Therapy with or without Cisplatin in Treating Patients with Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Cancer Type
Head and Neck Cancer
NCT ID
NCT02734537
Protocol IDs
EA3132
NCI-2015-01911
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
28.
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
Cancer Type
Head and Neck Cancer
NCT ID
NCT03754933
Protocol IDs
PNP-002
NCI-2019-01328
14271
R01FD005746-01A1
29.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
30.
NCORP Trial
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT01810913
Protocol IDs
RTOG 1216
NCI-2013-00500
U10CA021661
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
31.
NCORP Trial
Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03811015
Protocol IDs
EA3161
EA3161
NCI-2019-00179
Treatment Sites (4)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
32.
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients with Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT04533750
Protocol IDs
NRG-HN008
NRG-HN008
NCI-2020-06481
33.
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab with or without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
Cancer Type
Head and Neck Cancer
NCT ID
NCT05063552
Protocol IDs
EA3202
EA3202
NCI-2021-10021
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
34.
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy with Radiation after Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT04671667
Protocol IDs
EA3191
EA3191
NCI-2020-13174
35.
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT04338399
Protocol IDs
AN2025H0301
NCI-2021-07462
36.
Tolinapant and Radiation Therapy for the Treatment of Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05245682
Protocol IDs
WINSHIP5380-21
NCI-2021-09678
STUDY00002992
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Clinical Trials & Providers

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.